Acumen Pharmaceuticals, Inc. (ABOS) dividends
ABOS on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Acumen Pharmaceuticals, Inc. dividend: key facts
Own Acumen Pharmaceuticals, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next ABOS dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- ProMIS Neurosciences price target lowered to $15 from $29 at Roth Capital2 Nov 2026 · TheFly
Roth Capital lowered the firmâs price target on ProMIS Neurosciences (PMN) to $15 from $29 and keeps a Buy rating on the shares following Acumenâs (ABOS) failed Phase 2 studyâ¦
- Acumen price target lowered to $1 from $8 at BTIG2 Nov 2026 · TheFly
BTIG analyst Thomas Shrader lowered the firmâs price target on Acumen (ABOS) to $1 from $8 and keeps a Buy rating on the shares. The firm cites the ALTITUDE-AD studyâ¦
- Acumen downgraded to Underperform from Buy at BofA2 Nov 2026 · TheFly
BofA double downgraded Acumen (ABOS) to Underperform from Buy with a price target of $1, down from $8. The firm says sabirnetugâs Phase 2 miss âraises hard questions for Acumenâ¦
- Acumen downgraded to Neutral from Buy at Lucid Capital2 Nov 2026 · TheFly
Lucid Capital analyst Dev Prasad downgraded Acumen (ABOS) to Neutral from Buy with a price target of $1, down from $7. The firm cites the âdisappointingâ results from Acumenâs Phaseâ¦
- Acumen reports ALTITUDE-AD clinical trial did not meet primary endpoint30 Oct 2026 · TheFly
Acumen (ABOS) announced that initial topline data from its Phase 2 ALTITUDE-AD clinical trial of sabirnetug in participants with early AD did not meet its primary endpoint of change fromâ¦
- Acumen downgraded to Underweight from Overweight at Cantor Fitzgerald30 Oct 2026 · TheFly
Cantor Fitzgerald downgraded Acumen (ABOS) to Underweight from Overweight without a price target after sabirnetug failed to hit primary and key secondary endpoints in the Phase 2 Alzheimerâs disease s...
- Acumen downgraded to Neutral from Buy at Citi30 Oct 2026 · TheFly
Citi analyst Geoff Meacham downgraded Acumen (ABOS) to Neutral from Buy with a price target of $1, down from $5, after the sabirnetug Phase 2 trial did not meet theâ¦
- Acumen downgraded to Hold from Buy at Stifel30 Oct 2026 · TheFly
Stifel downgraded Acumen (ABOS) to Hold from Buy with a price target of $1, down from $10, following the companyâs announcement that both the 35mg/kg and 50mg/kg doses for sabirnetugâ¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 13 Nov 2026.